小分子靶向药物:银屑病治疗的新选择  

Small-molecule targeted agents:new choices for the treatment of psoriasis

作　　者：俞晨[1] 王刚[1] Yu Chen;Wang Gang(Department of Dermatology,Xijing Hospital,The Fourth Military Medical University,Xi'an 710032,China)

机构地区：[1]第四军医大学西京皮肤医院,西安710032

出　　处：《中华皮肤科杂志》2022年第9期747-751,共5页Chinese Journal of Dermatology

摘　　要：随着免疫学和分子生物学的飞速发展,银屑病发病机制研究取得了显著的进步,靶向发病机制中关键分子的治疗策略也取得了很大的成功。除生物制剂外,银屑病小分子靶向药物日益受到关注,以磷酸二酯酶4、Janus激酶、酪氨酸激酶2等为主要靶分子,越来越多的候选药物在研究中观察到较好的疗效,部分药物已获批用于临床,在银屑病的治疗中发挥独特的作用。With the rapid development of immunology and molecular biology in recent years,great progress has been made in the research on psoriatic pathogenesis,as well as in therapeutic strategies targeting key molecules in the pathogenesis.In addition to biologics,small-molecule targeted agents for psoriasis have also received increasing attention,especially agents targeting phosphodiesterase 4,Janus kinase,and tyrosine kinase 2,etc.An increasing number of small-molecule drug candidates have shown favorable efficacy in clinical studies,and some of them have been approved for clinical application and play a unique role in the treatment of psoriasis.

关 键 词：银屑病 磷酸二酯酶4抑制剂 Janus激酶抑制剂 酪氨酸激酶2抑制剂 小分子药物 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]